{"name":"Amryt Pharma","slug":"amryt-pharma","ticker":"","exchange":"","domain":"","description":"Amryt Pharma is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for patients with rare and orphan diseases. The company's lead product, Filsuvez, is currently marketed for the treatment of Epidermolysis Bullosa, a severe genetic skin disorder.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Filsuvez","genericName":"birch bark extract","slug":"birch-bark-extract","indication":"Epidermolysis bullosa","status":"marketed"},{"name":"Filsuvez","genericName":"Filsuvez","slug":"filsuvez","indication":"Epidermolysis bullosa","status":"marketed"}]}],"pipeline":[{"name":"Filsuvez","genericName":"birch bark extract","slug":"birch-bark-extract","phase":"marketed","mechanism":"Filsuvez works by targeting the underlying cause of Epidermolysis bullosa to reduce skin blistering.","indications":["Epidermolysis bullosa"],"catalyst":""},{"name":"Filsuvez","genericName":"Filsuvez","slug":"filsuvez","phase":"marketed","mechanism":"Small molecule","indications":["Epidermolysis bullosa"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5XdVZNOFo3NG9zZTA2UnRpUG9FMHF6QlZUTXZ0bW16T3FiM2RoVEVRRnZkdVJTQWFsRVBBQTl5VE5LR1dDQWY1TGNUYzRiWTJKdWlV?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"AMYT Stock Price, News & Analysis - Stock Titan","headline":"AMYT Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOdDFkNnRiNzJEY3JueFNka2ZWVlhPalVDSXNWNVBocFJlUGl2YXNMQzAzOFRRTnBoMGN5NU51UVQ1ZlU4NVRjVUZXQVVwY0dJNzdTckxENVFFM2RIRFlfby0tYnNCekJ2UzRTT2RCdkF1cWhaUkZqZFdZZHEtUUtfWjJoSHpEY1NiWjgzQy0wdVphZw?oc=5","date":"2023-12-20","type":"regulatory","source":"BioSpace","summary":"Chiesi’s $1.25B Amryt Buy Pays Off with FDA Approval of Filsuvez - BioSpace","headline":"Chiesi’s $1.25B Amryt Buy Pays Off with FDA Approval of Filsuvez","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPenExaXpPQ0I0aDluMl9MTXQ2V1p4ajlrUkxnOVZaRmJ3SmdGVFlwYWFqcFBZdW51RTBveVpzZ0xydGVzdFJURHVwcHVPNjdNdjRIRjJYNmxISUJSYkswdlBwQUZ1N25HV1lheENfelZNOERaeFhpVmpvak5oVEtlRXFRV2Y2VEp5cmJVOExwWlBXYkdSel80T1YyUTZ5eTk1RW9DTGYtekd4SlpRMkZlOWVDU0NPaDAzZnZhcm1QYw?oc=5","date":"2023-04-12","type":"deal","source":"drugdiscoverytrends.com","summary":"Chiesi acquires Amryt pharma to boost rare disease therapy focus - drugdiscoverytrends.com","headline":"Chiesi acquires Amryt pharma to boost rare disease therapy focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPVEpabVcxclZ1aENmOGNiQTlGdE5iRWg1M3cyVHZTTEwxT3VLaUdVLWR1QzZEaDdNaDVhejExd2FfYTNJaGZydEpXLU1iX0RtZGRpMVQ3WFVrNE4tZ05BQzREWG1BUktQeEJOamlDdklHUk5MOWpRN2pTS0NXbklQX1FTWU9tVHlfaDJoTlFwZkpEMi1KZ3c?oc=5","date":"2023-03-22","type":"regulatory","source":"Yahoo Finance","summary":"Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici - Yahoo Finance","headline":"Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9sSjVBc2R0NXhGd3R0bDlRQUc0S0tFY1hzNmRHdGJqUkhuWTU2SGxCRFV4blYwQnY5clpNeVZiQXZUT0h2aXEwQ09BU1piS2NxMWpGTnRSS3pONkxhZDBTLWZJa0ZNZU5xZ1dBcGRHQ0FmYjlRaUowZmRGdw?oc=5","date":"2023-01-09","type":"deal","source":"Pharmaceutical Technology","summary":"Chiesi Farmaceutici agrees to buy Amryt Pharma for $1.48bn - Pharmaceutical Technology","headline":"Chiesi Farmaceutici agrees to buy Amryt Pharma for $1.48bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOV1l3Qzk2bUI0TFRzZ3RFRFJjNndESG00TE51S2xIaWU0UGJyV2RWRGc4TUNmaVhFRklRTWdDYVFSVkMyWXE1N1duRzdpdjVaaUt5bm5aZC1mUXpZZWRDZ1BqX210Zm1tZWVYSnJjbHhWVTNuYnpXVHRiSnFYeFBuRk9udWZFUDlXSTNxTTlUaXhUZHRROGdvQnRXMmJhdw?oc=5","date":"2023-01-09","type":"pipeline","source":"pharmaphorum","summary":"Chiesi expands rare disease portfolio with Amryt Pharma acquisition - pharmaphorum","headline":"Chiesi expands rare disease portfolio with Amryt Pharma acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPZ0pjNHgybmFKbzdZTk1oaGdGd2pQZHFNZ09LOHNpU0hMQkRQUzcxZ2JuZGw0ZHB5ME9oV1QyTnNSN2F1Q2hiaUhvOVE3QWI0c05ZNmpESG5EcDEybkxXOHBzZG5hUlhMd3NNNzljbWE1Y2tTSVpadVQ1QTVWMnFnSE93SF9vRkFJSFpUYV93?oc=5","date":"2023-01-09","type":"deal","source":"Fierce Pharma","summary":"JPM23: Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout - Fierce Pharma","headline":"JPM23: Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQMHo5OXhBZjZqNl9IUGRYUGJmWHliQmljQUZOYzNiTC1xUGtnTl9zQkEtS3J1MFcxUXlENzdkY2ZTQ1BHNWR0WWI1VUZFa3N2MHJTaTRyWWJUTElxeFFqcmFDTzBfRmJCc2toQkdSaWphY05IRHpfRHVSLVp5c1hYUE95VUw4ekRSN1J6ZEozbjJsd2JqbHJOTnNxVlAxWWFwVHFV?oc=5","date":"2023-01-09","type":"deal","source":"The Irish Times","summary":"Irish rare disease drugmaker Amryt Pharma to be acquired for up to €1.4bn - The Irish Times","headline":"Irish rare disease drugmaker Amryt Pharma to be acquired for up to €1.4bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQQ3FzcmM3TGRBa09XSkp6TXYxYlZxRE0yaUlLSWs2eDg2dFNycnllUGJnYWpUc3BGWTEwUkFWc3FOcVhtX1haWWJSUDNCTGlaMEl4TTh2U1MySDI4TG9FUW1KdHdQY2V5TTQwQk9mMzRDeWtVazBPdHNNS003a1lnejlPSldwRTl5dEtLTVJBUndBNFNaQjBPdzh3XzVyTjNzWHlFMExpajdGekdXUG53UlFaVW1iMU5sOFY4RF9MY2tvZ0U?oc=5","date":"2023-01-08","type":"deal","source":"GlobeNewswire","summary":"Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc - GlobeNewswire","headline":"Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1fWHU1cmxPU1BqLVlCM2VTekpvUExyYUx2N2RKTUFYbTYtY2M2YUI2Y2J1VDdWS2F5dTZCMVdsWjVxckI4cGtmbmgxYkItNktPUEstVFdPUDlLNXJwT3NoU2N2Y0E0c1ZJdXdMS3ZadU9YOFlXSjc1ZUlKblZtUQ?oc=5","date":"2022-11-15","type":"pipeline","source":"Labiotech.eu","summary":"A new treatment for tackling epidermolysis bullosa - Labiotech.eu","headline":"A new treatment for tackling epidermolysis bullosa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxONzFUVzQ3ZVdNYzJveXVwbDRmR2ZjNFA5MlR6bXFtTEs5WkdxQ0UtZ3ZrRFFOYlZHS01DWlNvT3hEallsbXczck00MDBIYmZiaTlwSHN2OXppTm1BWUlvUmd3Y01FTkZUc1BTZmd2YnpUOGxURXNDZGl4Y3NaeXhGdEZaVElLZXpQRU85bXQybjAtQWtXNVM2NEdnUEtNOExNc0djdGFySUdiZmFUM3d3Rw?oc=5","date":"2021-05-06","type":"pipeline","source":"The Times","summary":"Rare disease rivals Amryt Pharma and Chiasma to merge - The Times","headline":"Rare disease rivals Amryt Pharma and Chiasma to merge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOdERQclhBS29FMXhoTHpCWjZuVWNrNWFfbXpMSW9GQkNMWlpsZnBDeXgtRFZ2MnBoeEFCdnZmd0dEc3dTb1VUWUJjbDZiV2Z2c00xdDU3TXpSeUE0M0FMZWp6MlVzZEtzT1h6RjMzZFJxNVpKNWNTdDVqQlBacFJrdkR0QVlxMm1RWXRDamdNYi1CdW1PZzlVX0FYWGJYckZQdmc?oc=5","date":"2019-09-25","type":"deal","source":"Fierce Biotech","summary":"Amryt buys Aegerion via bankruptcy, adding sales to support R&D - Fierce Biotech","headline":"Amryt buys Aegerion via bankruptcy, adding sales to support R&D","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}